Literature DB >> 1919681

Oligodendrogliomas.

D Margain1, P Peretti-Viton, A M Perez-Castillo, P Martini, G Salamon.   

Abstract

Oligodendrogliomas are tumours developed from oligodendrocytes. They may be pure or associated with astrocyte proliferation. They are usually benign, but their malignancy grade is varied. These tumours affect middle-aged adults and are characterized by their slow growth and their fairly suggestive neuroradiological features which are those of a large, calcified, poorly enhanced, peripheral frontal lesion. Computerized tomography and magnetic resonance imaging are suitable complementary methods to characterize the tumour and evaluate its extension.

Entities:  

Mesh:

Year:  1991        PMID: 1919681

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  4 in total

1.  Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging.

Authors:  M Zulfiqar; N Dumrongpisutikul; J Intrapiromkul; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

2.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.

Authors:  Ki-Young Choi; Tae-Young Jung; Shin Jung; Young-Hee Kim; Kyung-Sub Moon; In-Young Kim; Sam-Suk Kang; Kyung-Hwa Lee
Journal:  J Neurooncol       Date:  2010-08-25       Impact factor: 4.130

4.  Diagnostic performance of susceptibility-weighted magnetic resonance imaging for the detection of calcifications: A systematic review and meta-analysis.

Authors:  Lisa C Adams; Keno Bressem; Sarah Maria Böker; Yi-Na Yvonne Bender; Dominik Nörenberg; Bernd Hamm; Marcus R Makowski
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.